PI-CAI: AI matches or beats radiologists in prostate cancer detection on MRI
In a reader study with 62 radiologists on 400 cases, the AI detected about 6.8% more clinically significant cancers at the same specificity and produced about 50% fewer false positives. On 1,000 routine-practice cases, however, non-inferiority was not confirmed (specificity 68.9% vs 69.0% at 96.1% sensitivity). The authors call for prospective validation, and the system is not available for clinical use.
Technology: PI-CAI challenge super-algorithm (ensemble of top five submitted deep learning models)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A multireader study with 62 radiologists on 400 paired cases compared AI and PI-RADS 2.1 reads, and 1,000 routine-practice cases were used to test non-inferiority against historical clinical readings.
- Still unknown: Non-inferiority to routine practice was not confirmed (specificity 68.9% vs 69.0%); the authors state prospective validation is needed and the system is not available for clinical use.
- AI role: A deep-learning system detected clinically significant prostate cancer on MRI.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:38876123%20AND%20SRC:MED&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 418 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.